Welcome to our dedicated page for Baird Medical news (Ticker: BDMD), a resource for investors and traders seeking the latest updates and insights on Baird Medical stock.
Baird Medical Investment Holdings Ltd (NASDAQ: BDMD) is closely associated with minimally invasive Microwave Ablation (MWA) technology for the treatment of benign and malignant tumors. The BDMD news page on Stock Titan aggregates company-specific updates so readers can follow how Baird Medical’s medical devices and minimally invasive treatment technologies are being used and introduced in clinical settings around the world.
News about Baird Medical often highlights clinical milestones, such as first procedures in new countries, successful thyroid and liver tumor ablations, and applications of its MWA systems in bone tumor cases. Releases also describe physician training initiatives, including advanced MWA training sessions and participation in international workshops focused on thyroid microwave ablation and thermal ablation techniques.
Another recurring theme in BDMD news is global expansion and regulatory progress. The company reports regulatory approvals and product registrations in markets such as Pakistan and Vietnam, as well as entry into countries including Egypt and Bangladesh. Announcements have also covered the establishment of a U.S. manufacturing base through a partnership with MPS Medical to support worldwide supply of its proprietary technologies.
Investors and healthcare professionals can use this news feed to monitor developments related to Baird Medical’s microwave ablation devices, its presence in leading hospitals and clinics, and its broader commercialization and training activities. For ongoing insight into BDMD stock from a news perspective, this page provides a focused view of the company’s clinical, regulatory, and operational updates.
Baird Medical (NASDAQ: BDMD) executed two expert-led clinical training workshops in Indonesia on March 16, 2026. The sessions at EKA Medika Hospital and RSCM Rumah Sakit Nasional Dr. Cipto Mangunkusumo Hospital delivered hands-on instruction in minimally invasive Microwave Ablation (MWA) platforms.
Attending physicians practiced MWA techniques for a variety of soft tissue conditions to support regional adoption and smoother clinical integration of Baird Medical's technologies across Southeast Asia.
Baird Medical (NASDAQ: BDMD) announced regulatory clearance of its minimally invasive Microwave Ablation systems in Argentina on March 12, 2026. This approval expands the company’s international certifications beyond the United States FDA to include Indonesia, Malaysia, and Vietnam.
According to the company, Baird Medical is pursuing formal registration in Egypt, Sri Lanka, the Philippines, Pakistan, and other markets to broaden global patient access to its MWA technology.
Baird Medical (NASDAQ: BDMD) reported a strategic showcase at the 2026 North American Society for Interventional Thyroidology (NASIT) in Portland, advancing its U.S. expansion for minimally invasive microwave ablation (MWA) technology. The company highlighted clinical applications at a thermal ablation workshop and engaged Key Opinion Leaders and emerging physicians.
Leadership said the engagements aim to accelerate adoption of precision, non-surgical interventions to expand patient access and elevate standards of care across the United States.
Baird Medical (NASDAQ: BDMD) announced completion of development for its cross-platform, AI-driven surgical software and has begun regulatory registration in the United States, European Union, and China on March 4, 2026. The system automates anatomical mapping, dynamic treatment planning, and procedural simulations using a proprietary AI model.
The software integrates diverse diagnostic imaging and is engineered to connect with Baird Medical's upcoming automated surgical robotic system, aiming to create a closed-loop surgical ecosystem spanning pre-, intra- and post-operative workflows and to accelerate the company's commercial roadmap.
Baird Medical (NASDAQ: BDMD) highlighted its U.S. expansion strategy by participating at the NASOIE 2026 Annual Meeting in Miami on March 2, 2026.
The company engaged clinicians on its proprietary microwave ablation (MWA) technology, gathered clinical feedback, and said that insights will inform its commercial roadmap to expand patient access to minimally invasive therapies.
Baird Medical (NASDAQ: BDMD) announced expanded clinical progress across the United States on Feb 25, 2026, supporting its strategy to grow U.S. adoption of minimally invasive microwave ablation (MWA) for benign thyroid conditions.
Clinical use by Samer Nakhle, M.D., in Las Vegas and Sophie Dream, M.D., at UAB are cited as milestones reinforcing commercial rollout and broader physician access, with US CEO Mark Saxton saying the integrations validate the company’s commercial roadmap.
Baird Medical (NASDAQ: BDMD) will showcase its minimally invasive Microwave Ablation (MWA) thyroid solutions at three U.S. clinical conferences in late Feb–March 2026. The company plans live demonstrations and clinician engagement to promote needle-based treatments for benign thyroid nodules that avoid traditional surgery and scarring.
Events: NASOIE Feb 27–28 Miami, NASIT Mar 6–7 Portland, ISITES Mar 11–13 Washington, D.C.
Baird Medical (NASDAQ: BDMD) announced a commercial launch of its minimally invasive Microwave Ablation (MWA) platform at Bakersfield Memorial Hospital on February 11, 2026. The hospital performed the first U.S. Benign Thyroid Tumor ablation in central California, led by Tim Beck, M.D., demonstrating procedural success and safety.
The deployment advances Baird Medical's U.S. commercial roadmap and expands its footprint in the San Joaquin Valley, aiming to accelerate patient access to interventional therapies in high-volume regional centers.
Baird Medical (NASDAQ: BDMD) announced clinical education programs in the U.S. and Japan to accelerate global adoption of its Microwave Ablation (MWA) technology for benign thyroid tumors. The company led advanced training at Columbia University and a workshop at Showa Medical University to standardize interventional thyroidology techniques and expand non-surgical patient options.
Baird Medical (NASDAQ: BDMD) concluded a Gynecological Microwave Ablation Masterclass in Shanghai on January 28, 2026, led by Dr. Xiaoming Gong. The program combined didactic lectures and live case observations to train physicians across Asia in the company's proprietary microwave ablation technology.
The event reinforces Baird Medical's focus on physician education, expansion of minimally invasive women's health treatments, and broader commercial presence, noting FDA 510(k) certification and use in over 30 U.S. hospitals and in more than 20 countries.